New York Batch 5

IBNY05’s In-Person Preview will take place on Feb 1, 2023, and our Online Demo Day will be on Feb 7, 2023. Please sign up for our newsletter to get exclusive announcements from our companies and for Demo Day. Updated Jan 19, 2023.

Curing the Untreated

Almost 85% patients with late-stage cancers do not have treatment options.

A new wave of RNA therapeutics has the potential to transform treatment for solid tumours. Existing non-viral technologies cannot target tumour cells. Moreover, these fail to release the therapeutic RNA into the cytosol, less than 1% leaks out of the endosomes (a sub-cellular compartment). The remaining 99% is degraded.

EndoPore is Vitarka Therapeutics’ solution to this drug delivery problem. Using a synthetic biology approach, our team has developed pore forming proteins (PFPs) for targeted, cytosolic delivery of RNA therapeutics. PFPs have a naturally evolved mechanism of endosomal escape, which we are exploiting along with using a validated mechanism of stabilising RNA.

Source URL: https://indiebio.co/cohort/ibny05-2022/